Anavex Stock Price Crash: A Fault By Trial Design?
Executive Summary
Anavex Life Sciences' unabashed self-promotion since late-2015 for its leading pipeline product ANAVEX 2-73, which is being studied as a treatment for Alzheimer's disease, may have been one reason the firm's stock crashed down this week following the presentation of Phase IIa data at the Alzheimer's Association International Conference. But the study with no control arm and only 32 patients for a neurological disorder also has some analysts questioning how robust the data are.
You may also be interested in...
Anavex Finds EXCELLENCE Trial To Be Ironically Named
A failure in children with Rett syndrome sees the company’s market value cut by more than a third.
Anavex Reveals Positive Phase III Data In Rett Syndrome But A Surprise Endpoint
The endpoint used in the AVATAR trial was different than the one investors had expected; management said the change was made to satisfy the US FDA.
After Solanezumab, What’s Next? Alzheimer’s Options Take The Stage At CTAD
Lilly will make its first presentation of solanezumab data from the recently failed Phase III EXPEDITION3 study during the Clinical Trials in Alzheimer’s Disease meeting where researchers will discuss amyloid beta and other hypotheses in Alzheimer’s disease Dec. 8-10 in San Diego.